Citations

Clear

959 citation(s) found for "Service, F J".

Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
Bertamini, Luca, Murphy, Ciara, Fleming, Grace, Perry, Jacqueline , Cea-Curry, Christian J., Pentz, Audrey , Hlubi, Thulisile, Smyth, Natalie , Sakrikar, D.J., Perkins, Mark, Troske, Derek, Chen, Carl Wenlong, Bertamini, Luca , Alberge, Jean-Baptiste , El‐Khoury, Habib , Lee, David Jungpa , Davis, Maya , Harding, Stephen E. , Getz, Gad , Rebbeck, Timothy R. , Joffe, Maureen , Marinac, Catherine R. , Leung, Nelson , Ghobrial, Irene M.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10005-10006

10.1182/blood-2022-164436 Get It

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Usmani, Saad Z. , Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, Fredrik, Kumar, Shaji , Usmani, Saad , Moreau, Philippe , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Raje, Noopur , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Weisel, Katja C , Frenzel, Laurent

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7297-7300

10.1182/blood-2022-163494 Get It

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Munshi, Nikhil C. , Martin, Thomas G. , Usmani, Saad Z. , Lin, Yi , Schecter, Jordan M. , Jackson, Carolyn C. , Zudaire, Enrique, Yeh, Tzu‐Min, Bartlett, J. Blake , Pacaud, Lida , Geng, Dong , Usmani, Saad , Paiva, Bruno , Madduri, Deepu , Akram, Muhammad , Jagannath, Sundar , Cohen, Adam D. , Miguel, Jesús F. San

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4652-4654

10.1182/blood-2022-159141 Get It

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Roussel, Murielle , Delforge, Michel, Karlin, Lionel , Arnulf, Bertrand , Pei, Huiling , Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S. , Carson, Robin, Borgsten, Fredrik, Usmani, Saad , Roussel, Murielle , Perrot, Aurore , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Jaccard, Arnaud , Chari, Ajai , Weisel, Katja C

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1142-1145

10.1182/blood-2022-165524 Get It

Liquid Chromatography–Tandem Mass Spectrometry in Newborn Screening Laboratories
Basheeruddin, Khaja, Burlina, Alberto , Chen, Hsiao-Jan, Dizikes, George J. , Dorley, M. Christine , Giugliani, Roberto , Hietala, Amy, Kao, Shu‐Min, Klug, Tracy, Kubaski, Francyne , Liao, Hsuan-Chieh , Martin, Monica, Manning, Adrienne, Orsini, Joseph J. , Peng, Yin , Ranieri, Enzo , Rohrwasser, Andreas , Szabo‐Fresnais, Nicolas, Turgeon, Coleman , Wang, Liyun , Matern, Dietrich , Burlina, Alberto , Chien, Yin-Hsiu , Dorley, Christine , Giugliani, Roberto , Kubaski, Francyne , Turgeon, Coleman T, Matern, Dietrich , Gelb, Michael H. , Hong, Xinying , Khaledi, Hamid , Vaz, F

Mayo Clinic

International Journal of Neonatal Screening | November 28, 2022 | Volume: 8 | Issue: 4 | Pages: 62

10.3390/ijns8040062 | PMID 36547379 Get It

Tandem mass spectrometry (MS/MS) is the most universal platform currently available for the analysis of enzymatic activities and biomarkers in dried blood spots (DBS) for applications in newborn screening (NBS). Among the MS/MS applications in NBS, the most common is flow-injection analysis (FIA-) MS/MS, where the sample is introduced as a bolus injection into the mass spectrometer without the prior fractionation of analytes. Liquid chromatography combined with MS/MS (LC-MS/MS) has been employed for second-tier tests to reduce the false-positive rate associated with several nonspecific screening markers, beginning two decades ago. More recently, LC-MS/MS has been applied to primary screening for new conditions for which FIA-MS/MS or other methods, including genomic screening, are not yet adequate. In addition to providing a list of the currently used LC-MS/MS-based assays for NBS, the authors share their experience regarding the maintenance requirements of LC-MS/MS vs. FIA-MS/MS systems. The consensus is that the maintenance of LC-MS/MS and FIA-MS/MS instrumentation is similar, and LC-MS/MS has the advantage of allowing for a larger number of diseases to be screened for in a multiplex, cost-effective fashion with a high throughput and an adequate turnaround time.
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
Day, Julia, Gehring, Karin , Zienius, Karolis , Grosshans, David R. , Taphoorn, Martin, Li, Jing , Brown, Paul D. , Kirkman, Matthew Anthony , Taphoorn, Martin

Mayo Clinic

Cochrane Database of Systematic Reviews | November 25, 2022 | Volume: 2022 | Issue: 11 | Pages: No page available

10.1002/14651858.cd011335.pub3 | PMID 36427235 Get It

Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer
Niranjan, Ajay , Hess, Judith, Antonios, Joseph , Zhang, Michael Y. , Ross, Richard B. , Pikis, Stylianos , Deibert, Christopher P., Lee, Cheng-chia, Langlois, Anne-Marie, Mathieu, David , Peker, Selçuk , Samancı, Yavuz , Rusthoven, Chad G. , Chiang, Veronica , Wei, Zhishuo , Lunsford, L. Dade , Sheehan, Jason P. , Mathieu, David , Kowalchuk, Roman O. , Braunstein, Steve , Yang, Huai‐Che , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | November 25, 2022 | Volume: 138 | Issue: 6 | Pages: 1608-1614

10.3171/2022.10.jns221900 | PMID 36433878 Get It

OBJECTIVE Stereotactic radiosurgery (SRS) is an effective treatment for intracranial metastatic disease, but its role in triple-negative breast cancer requires further study. Herein, the authors report overall survival (OS) and local tumor control in a multiinstitutional cohort with triple-negative breast cancer metastases treated with SRS. METHODS Patients treated from 2010 to 2019 at 9 institutions were included in this retrospective study if they had biopsy-proven triple-negative breast cancer with intracranial metastatic lesions treated with SRS. Patients were excluded if they had undergone prior SRS, whole-brain radiation therapy, or resection of the metastatic lesions. A retrospective chart review was conducted to determine OS, local control, and treatment efficacy. RESULTS Sixty-eight patients with 315 treated lesions were assessed. Patients had a median Karnofsky Performance Status of 80 (IQR 70–90) and age of 57 years (IQR 48–67 years). Most treated patients had 5 or fewer intracranial lesions, with 34% of patients having a single lesion. Treated lesions were small, having a median volume owf 0.11 cm3 (IQR 0.03–0.60 cm3). Patients were treated with a median margin dose of 18 Gy (IQR 18–20 Gy) to the median 71% isodose line (IQR 50%–84%). Overall, patients had a 1-year OS of 43% and 2-year OS of 20%. Most patients (88%) were followed until death, by which time local tumor progression had occurred in only 7% of cases. Furthermore, 76% of the lesions demonstrated regression. Tumor volume was correlated with local tumor progression (p = 0.012). SRS was very well tolerated, and only 3 patients (5%) developed symptomatic radiation necrosis. CONCLUSIONS SRS is a safe and efficacious treatment for well-selected patients with triple-negative breast cancer, especially for those with a favorable performance status and small- to moderate-volume metastatic lesions.
Monitoring and diagnosis of intermittent arrhythmias: evidence-based guidance and role of novel monitoring strategies
Carrington, M , Providência, Rui , Epstein, Andrew E. , Gallina, Sabina , Fedorowski, Artur , Sutton, Richard , Carrington, Mafalda , Fedorowski, Artur , Sutton, Richard , Providencia, Rui , Chahal, C. Anwar A. , Ricci, Fabrizio , Khanji, Mohammed Y

Mayo Clinic

European Heart Journal Open | November 12, 2022 | Volume: 2 | Issue: 6 | Pages: No page available

10.1093/ehjopen/oeac072 | PMID 36440351 Get It

Abstract Technological advances have made diagnosis of heart rhythm disturbances much easier, with a wide variety of options, including single-lead portable devices, smartphones/watches to sophisticated implantable cardiac monitors, allowing accurate data to be collected over different time periods depending on symptoms frequency. This review provides an overview of the novel and existing heart rhythm testing options, including a description of the supporting evidence for their use. A description of each of the tests is provided, along with discussion of their advantages and limitations. This is intended to help clinicians towards choosing the most appropriate test, thus improving diagnostic yield management of patients with suspected arrhythmias.
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
Belhadj, Sami , Khurram, Aliya , Bandlamudi, Chaitanya , Palou-Márquez, Guillermo , Steinsnyder, Zoe , Wildman, Temima , Catchings, Amanda , Kemel, Yelena , Mukherjee, Semanti , Fesko, Benjamin , Mehine, Miika , Dandiker, Sita , Izhar, Aalin , Nathanson, Katherine L. , Brower, Jamie , Walsh, Michael F. , Topka, Sabine , Offit, Kenneth , Ravichandran, Vignesh , Steinsnyder, Zoe , Wildman, Temima , Catchings, Amanda , Kemel, Yelena , Mukherjee, Semanti , Fesko, Benjamin , Arora, Kanika , Mehine, Miika , Dandiker, Sita , Izhar, Aalin , Petrini, John , Domchek, Susan M , Nathanson, Katherine L , Brower, Jamie , Couch, Fergus J. , Stadler, Zsofia , Robson, Mark , Walsh, Michael , Joseph, Vijai , Berger, Michael , Supek, Fran , Karam, Rachid , Topka, Sabine , Offit, Kenneth , Ravichandran, Vignesh , Domchek, Susan M. , Couch, Fergus J. , Robson, Mark E. , Vijai, Joseph , Karam, Rachid

Mayo Clinic

Clinical Cancer Research | November 8, 2022 | Volume: 29 | Issue: 2 | Pages: 422-431

10.1158/1078-0432.ccr-22-1703 | PMID 36346689 Get It

Abstract Purpose: To explore the role of NBN as a pan-cancer susceptibility gene. Experimental Design: Matched germline and somatic DNA samples from 34,046 patients were sequenced using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and presumed pathogenic germline variants (PGV) identified. Allele-specific and gene-centered analysis of enrichment was conducted and a validation cohort of 26,407 pan-cancer patients was analyzed. Functional studies utilized cellular models with analysis of protein expression, MRN complex formation/localization, and viability assessment following treatment with γ-irradiation. Results: We identified 83 carriers of 32 NBN PGVs (0.25% of the studied series), 40% of which (33/83) carried the Slavic founder p.K219fs. The frequency of PGVs varied across cancer types. Patients harboring NBN PGVs demonstrated increased loss of the wild-type allele in their tumors [OR = 2.7; confidence interval (CI): 1.4–5.5; P = 0.0024; pan-cancer], including lung and pancreatic tumors compared with breast and colorectal cancers. p.K219fs was enriched across all tumor types (OR = 2.22; CI: 1.3–3.6; P = 0.0018). Gene-centered analysis revealed enrichment of PGVs in cases compared with controls in the European population (OR = 1.9; CI: 1.3–2.7; P = 0.0004), a finding confirmed in the replication cohort (OR = 1.8; CI: 1.2–2.6; P = 0.003). Two novel truncating variants, p.L19* and p.N71fs, produced a 45 kDa fragment generated by alternative translation initiation that maintained binding to MRE11. Cells expressing these fragments showed higher sensitivity to γ-irradiation and lower levels of radiation-induced KAP1 phosphorylation. Conclusions: Burden analyses, biallelic inactivation, and functional evidence support the role of NBN as contributing to a broad cancer spectrum. Further studies in large pan-cancer series and the assessment of epistatic and environmental interactions are warranted to further define these associations.
NS2NS: Self-Learning for Seismic Image Denoising
Liu, Naihao , Wang, Jiale , Gao, Jinghuai , Yu, Kai , Lou, Yihuai , Pu, Yitao , Chang, Shaojie

Mayo Clinic

IEEE Transactions on Geoscience and Remote Sensing | November 3, 2022 | Volume: 60 | Issue: No issue available | Pages: 1-11

10.1109/tgrs.2022.3217289 Get It